GPR160 Antibody

What is GPR160 and why is it significant for research?

GPR160 is an orphan class A G-protein-coupled receptor (GPCR) previously annotated as GPCR1 or GPCR150. The human GPR160 protein consists of 338 amino acids and is encoded by 7 exons located at chromosome 3q26.2-q27 . GPR160 has gained significant research interest due to its identification as a potential receptor for cocaine- and amphetamine-regulated transcript peptide (CARTp) and its observed roles in various physiological processes including food intake regulation, water intake control, and pain modulation . Additionally, GPR160 has been implicated in tumorigenesis and metastasis of human cancers, particularly prostate cancer, making it a valuable target for both neurobiological and oncological research . Orthologues of GPR160 have been identified across multiple species including monkey, dog, cow, rat, mouse, chicken, zebrafish, and frog, indicating evolutionary conservation and functional importance .

How does one validate GPR160 antibody specificity?

Validating GPR160 antibody specificity requires a multi-method approach due to concerns about potential cross-reactivity with other GPCRs. Researchers have employed several complementary techniques to establish antibody specificity:

• siRNA knockdown: Demonstrating that the actions of CARTp (such as increasing cFos in KATO III cells and ERK phosphorylation in differentiated PC-12 cells) are significantly compromised by prior siRNA treatment targeting GPR160 .

• Co-immunoprecipitation: Showing that GPR160 immunoreactivity co-immunoprecipitates with fluorescently labeled CARTp .

• Proximity ligation assay: Confirming that CARTp colocalizes with GPR160 on cells .

• RNAscope analysis: Localizing GPR160 to specific cell types (neurons, microglia, and astrocytes) .

• Western blotting: Verifying that GPR160-targeting siRNA pretreatment decreases GPR160 protein levels in experimental cell lines .

Despite these validation methods, researchers should remain cautious, as the search results indicate: "we cannot rule out the possibility that other feeding-related peptides may interact with the same receptor" and "the GPR160 antibody... may interact with epitopes shared with several other GPCRs" .

Where is GPR160 expressed in the brain and how can this be detected?

GPR160 immunoreactivity (GPR160ir) has been detected throughout the rat brain in regions associated with multiple physiological functions:

Notably, GPR160ir was not observed in the nucleus accumbens core or the ventral tegmental area . Detection methods typically involve immunohistochemistry using validated antibodies such as Abcam Pa5-33650, which has been used for both passive immunoneutralization studies and immunohistochemical localization .

How does cell-type specific expression of GPR160 impact experimental design?

GPR160 expression has been detected in both neuronal and non-neuronal cell types, which significantly complicates experimental design and data interpretation. Research has shown GPR160 immunoreactivity in:

• Neurons: With varying expression levels depending on brain region (e.g., fewer neurons expressing GPR160 in the NTS compared to hypoglossal nucleus) .

• Astrocytes: Detected in cultured astrocytes and in tissue slices, with potential functional implications for glial-neuronal signaling .

• Microglia: Present in both cultured microglia and brain tissue slices, though expression levels differ between in vitro and in vivo conditions .

• Fibroblasts: Detected in astrocyte cultures, potentially explaining co-purification patterns .

This heterogeneous expression pattern necessitates careful experimental design considerations:

• Researchers should employ cell-specific markers (NeuN for neurons, GFAP for astrocytes, Iba1 for microglia) alongside GPR160 antibodies to determine cell-type specific localization .

• When examining functional effects, methods that can distinguish between neuronal and glial contributions are essential.

• As noted in the literature, "The fact that GPR160 is expressed on multiple cell types will increase the difficulty of identifying the relative influence of each cell type on the combined physiological output, and thus, the development of cell-specific knockdown approaches is required" .

• Experiments should consider both direct effects on GPR160-expressing neurons and indirect effects mediated through glial cells.

What approaches can be used to distinguish between GPR160-mediated and other GPCR signaling pathways?

Distinguishing GPR160-mediated signaling from other GPCR pathways requires specialized methodological approaches:

• Receptor expression in null systems: "Only when each potential candidate is expressed in cells null for the other receptors might this be established by detection of ligand (CARTp) binding and by demonstrating that signaling through that other receptor is not interrupted by the GPR160 antibody" .

• Targeted siRNA knockdown: Selective reduction of GPR160 expression using siRNA can help establish pathway specificity, as demonstrated in previous studies with KATO III cells and PC-12 cells .

• Proximity ligation assays: These can be used to determine physical association between specific ligands and GPR160 receptors, helping distinguish from interactions with other GPCRs .

• Pharmacological approaches with selective antagonists: Though not explicitly mentioned in the search results, selective antagonists (when developed) would provide tools to distinguish receptor-specific effects.

• Cell-specific genetic manipulation: Conditional knockout or knockdown of GPR160 in specific cell types can help parse out the relative contribution of GPR160 signaling pathways in different cellular contexts.

Researchers should be aware that "significant homologies do exist among members of this class of receptors," underscoring the importance of these specialized approaches for distinguishing GPR160-specific signaling from effects mediated by related GPCRs .

How do in vitro and in vivo GPR160 expression patterns differ, and what are the implications?

Research has identified notable differences between GPR160 expression patterns in vitro versus in vivo, with significant implications for experimental design and data interpretation:

• Microglia expression differences:

  • In cultured microglia: "GPR160ir was detected in the vast majority of cells"

  • In brainstem tissue slices: "GPR160ir was only observed in a small subset of microglia"

• Potential explanations for these differences:

  • "In nonnative conditions, cultured microglia may be more activated by physical manipulation"

  • Excess serum required for culture conditions may alter expression

  • Isolation from other cell types may impact receptor expression patterns

• Astrocyte cultures also showed potential differences, with fibroblast immunoreactivity detected, suggesting that "isolation and culture conditions may have increased artificially the immunoreactive content of the receptor and potentially the number of fibroblasts growing in the cultures" .

These differences have important implications:

• Caution is warranted when extrapolating from in vitro findings to in vivo conditions

• Validation of findings across both systems is recommended

• Experimental conditions should be carefully reported and considered during data interpretation

• The activation state of cells (particularly microglia) should be assessed and reported

• Mixed cell culture systems that better recapitulate in vivo cellular interactions may be preferable for certain research questions

What are the optimal protocols for passive immunoneutralization targeting GPR160?

Passive immunoneutralization using GPR160 antibodies has been employed to investigate the physiological roles of this receptor. Based on the search results, an established protocol includes:

• Target selection: The antibody (Pa5-33650, Thermo Fisher Scientific) targets the second extracellular loop of GPR160 to prevent CARTp from accessing potential binding sites .

• Administration route: Intracerebral injection into the fourth cerebroventricle (4V) of experimental animals .

• Dosage: 2 μL of saline containing 2 μg of GPR160 antiserum or IgG control .

• Timing considerations:

  • For blocking pharmacological effects: Administration 30 minutes before CARTp injection .

  • For physiological studies: Initial injection followed by a second injection 15-30 minutes later. This two-injection approach proved important as "sufficient antibody would need to be present once ingestion stimulated the endogenous release of CARTp from vagal afferents" .

• Control conditions: Parallel experiments using control IgG at equivalent concentrations .

• Behavioral measurements: Food and water intake recorded at regular intervals (e.g., every 30 minutes for acute studies, with an additional measurement the following morning for overnight effects) .

Researchers should note that timing of neutralization appears critical: "The failure of the same, single dose of anti-GPR160 that blocked the anorexigenic and antidipsogenic actions of pharmacologically altered ingestive behaviors to significantly alter physiologically driven feeding and drinking suggested that the timing of the neutralization was important" .

How can one distinguish between neuronal and non-neuronal GPR160 signaling effects?

Distinguishing between neuronal and non-neuronal GPR160 signaling effects requires specialized methodological approaches:

The complexity of these interactions is highlighted by the observation that "CART could be acting directly on GPR160-expressing hypoglossal motor neurons to slow ingestive behavior to an appropriate level throughout a discrete meal, assisting in timely meal termination" , illustrating just one potential mechanism among many possible cell-type specific effects.

What are the key considerations for designing GPR160 knockout or knockdown studies?

When designing GPR160 knockout or knockdown studies, researchers should consider several key factors:

• Cell-type specificity:

  • Given that GPR160 is expressed in multiple cell types, researchers should consider whether to target all GPR160-expressing cells or specific subpopulations.

  • The search results note that "the development of cell-specific knockdown approaches is required" .

• Temporal control:

  • Constitutive versus inducible systems should be considered, particularly since developmental compensation may occur in constitutive knockout models.

  • Temporal control may be especially important for studying acute versus chronic effects of GPR160 signaling.

• Regional specificity:

  • GPR160 is expressed throughout the brain in regions associated with different functions.

  • Site-specific manipulation (e.g., via stereotaxic injection of viral vectors) may be preferable to global knockdown for certain research questions.

• Sex differences:

  • The search results explicitly acknowledge: "We acknowledge that these studies were performed only in male rats and that future studies must address similar issues in female animals" .

  • Research should "examine the role of GPR160 expression in select brain sites in males and females across all 4 days of the estrous cycle using transgenic animals designed for that purpose" .

• Validation approaches:

  • Multiple methods should be used to confirm knockdown efficiency:

    • qPCR for transcript levels

    • Western blot for protein expression

    • Immunohistochemistry for spatial information

    • Functional assays to confirm physiological impact

• Controls for off-target effects:

  • Careful selection of control conditions to account for potential off-target effects of knockdown methods.

  • Rescue experiments to confirm phenotype specificity.

• Assessment of compensatory mechanisms:

  • Analysis of potential upregulation of related GPCRs that might compensate for GPR160 loss.

How might GPR160 antibodies be used to investigate neuronal-glial interactions in feeding regulation?

GPR160 antibodies present unique opportunities for investigating neuronal-glial interactions in feeding regulation, given the receptor's expression across multiple cell types:

• Triple-labeling immunohistochemistry approaches:

  • Using GPR160 antibodies alongside both neuronal and glial markers could reveal spatial relationships between GPR160-expressing cells of different types.

  • This could help identify potential "communication hubs" where GPR160-expressing neurons and glia are in close proximity.

• Selective manipulation studies:

  • Cell-type specific blockade of GPR160 (using antibodies delivered with cell-type specific vectors) could help dissect the relative contributions of neuronal versus glial GPR160 signaling.

  • Recent research suggests "DVC CART signaling may be mediated by Gpr160+ microglia, which in turn may be modulating DVC neuronal activity to control food intake" , providing a specific hypothesis that could be tested using selective antibody approaches.

• Ex vivo slice preparations:

  • Application of GPR160 antibodies to brain slices containing feeding-regulatory centers while recording neuronal activity could help elucidate how GPR160 blockade affects neuronal circuits.

  • Combining this with selective glial manipulation could reveal the contribution of glial GPR160 to neuronal function.

• In vivo fiber photometry or calcium imaging:

  • Using GPR160 antibodies while simultaneously recording neuronal and glial activity in freely feeding animals could provide insights into the temporal dynamics of GPR160-mediated cellular interactions during feeding.

• Investigation of regional differences:

  • The finding that "In the commissural NTS, GPR160 was observed predominantly in nonneuronal cells" while in other regions like the hypoglossal nucleus it appears more neuronal , suggests region-specific cellular interaction patterns that could be further explored using GPR160 antibodies.

These approaches could address the intriguing possibility that "some of the pharmacological actions described for CART peptides are mediated via an interaction with nonneuronal cells in the brain" , potentially revealing novel mechanisms of feeding regulation through neuronal-glial interactions.

What are the challenges in reconciling contradictory data on GPR160 function across different experimental paradigms?

Researchers face several challenges when reconciling contradictory data on GPR160 function across different experimental paradigms:

• Antibody specificity concerns:

  • The search results acknowledge that "it is possible that the GPR160 antibody used may interact with epitopes shared with several other GPCRs" .

  • This could lead to apparently contradictory results if different studies are actually measuring different receptor populations.

• Cell-type heterogeneity:

  • Given that GPR160 is expressed in both neuronal and non-neuronal cells, contradictory functional data may result from different cellular contributions across experimental paradigms.

  • The observation that GPR160 expression differs between in vitro and in vivo systems further complicates cross-study comparisons .

• Regional specificity issues:

  • GPR160 function may vary by brain region, with some areas showing predominantly neuronal expression and others predominantly glial expression .

  • Studies targeting different brain regions might therefore yield contradictory results.

• Methodological variations:

  • Different approaches to GPR160 manipulation (passive immunoneutralization, genetic knockdown, etc.) may produce different outcomes.

  • The specific timing of manipulations appears critical, as evidenced by the finding that single versus double antibody administration produced different effects on feeding .

• Sex differences:

  • The search results acknowledge studies were performed only in male rats and note the "abundant literature describing potential sex differences in ingestive behaviors" .

  • Data from males versus females might appear contradictory without accounting for hormonal influences.

To address these challenges, researchers should:

• Employ multiple, complementary approaches to manipulate and measure GPR160 function

• Clearly specify cell types, brain regions, sex, and methodological details in publications

• Consider potential interactions with other signaling systems

• Develop more selective tools for GPR160 targeting

• Directly test seemingly contradictory findings using identical experimental conditions

How can GPR160 antibodies be used to investigate potential therapeutic targets for metabolic disorders?

GPR160 antibodies offer several strategic approaches for investigating potential therapeutic targets for metabolic disorders:

• Metabolic phenotyping after targeted interventions:

  • Site-specific administration of GPR160 antibodies (particularly in hypothalamic and brainstem feeding centers) followed by comprehensive metabolic assessment could reveal region-specific contributions to energy homeostasis.

  • Parameters to measure include food intake, energy expenditure, glucose tolerance, and lipid metabolism.

• Mechanistic pathway elucidation:

  • The search results indicate that "the decrease in food intake, but not water intake, caused by central injection of CARTp was demonstrated to be interrupted by prior administration of a glucagon-like peptide 1 (GLP-1) receptor antagonist" .

  • This suggests interaction between GPR160 and GLP-1 signaling, a pathway already targeted by approved diabetes medications.

  • GPR160 antibodies could be used to further explore this interaction and potentially identify novel intervention points.

• Cell-specific metabolic effects:

  • Given GPR160's expression in multiple cell types, selective antibody targeting to specific cell populations could help identify the most therapeutically relevant cellular targets.

  • For example, comparing the metabolic effects of blocking GPR160 specifically in hypothalamic neurons versus astrocytes.

• Combination therapy exploration:

  • Using GPR160 antibodies alongside established metabolic drugs could reveal synergistic effects and inform combination therapy approaches.

  • The interaction with GLP-1 signaling mentioned above provides a starting point for such investigations.

• Diet-dependent effects:

  • Examining how GPR160 antibody administration affects metabolism differently under various dietary conditions (high-fat, ketogenic, high-carbohydrate) could identify context-specific therapeutic applications.

• Long-term versus acute intervention comparison:

  • Comparing the metabolic effects of acute versus chronic GPR160 blockade could distinguish between therapeutic approaches aimed at meal-by-meal regulation versus long-term metabolic adaptation.

These approaches align with the emerging understanding that GPR160 plays a significant role in feeding regulation, as evidenced by the finding that "passive immunoneutralization of GPR160 in the 4V blocked the actions of CARTp to inhibit food intake and water intake" and that blockade of GPR160 "independent of pharmacological CART treatment, caused an increase in both overnight food intake and water intake" .

What are the optimal immunohistochemistry protocols for GPR160 detection in different tissue types?

While the search results don't provide a complete immunohistochemistry protocol specifically for GPR160, they do offer insights into successful approaches that have been used. Based on this information and standard IHC principles, an optimal protocol would include:

• Antibody selection:

  • The antibody used successfully in the referenced studies was Pa5-33650 (Thermo Fisher Scientific) .

  • This antibody was validated through multiple approaches including siRNA knockdown, co-immunoprecipitation, and proximity ligation assays .

• Tissue preparation:

  • Standard paraformaldehyde fixation appears suitable, though specific fixation parameters aren't detailed in the search results.

  • For brain tissue, both fresh-frozen sections and fixed tissue slices have been used successfully .

• Cell-type specific detection:

  • Double-labeling approaches have been employed using the following markers:

    • NeuN for neurons

    • GFAP for astrocytes

    • Iba1 for microglia

• Special considerations for different tissues:

  • Brain tissue: GPR160 immunoreactivity was successfully detected throughout various regions including NTS, AP, parabrachial nucleus, hypoglossal nucleus, ARC, PVN, nucleus accumbens shell, substantia nigra, amygdala, hippocampus, and retrochiasmatic area .

  • Cell cultures: GPR160 immunoreactivity was detected in cultured astrocytes, microglia, and neurons, though expression patterns differed from in vivo tissues .

• Visualization methods:

  • The search results don't specify the exact visualization method, but both fluorescent and chromogenic detection systems are likely suitable.

  • For co-localization studies, fluorescent secondary antibodies with distinct emission spectra would be necessary.

• Controls:

  • Appropriate negative controls including omission of primary antibody

  • Preabsorption with immunizing peptide if available

  • Tissue from GPR160 knockout animals if available

  • Positive controls from tissues known to express GPR160 (e.g., prostate cancer cells for human tissue)

The search results indicate these methods have successfully localized GPR160 in various tissues, though researchers should be aware that "the Gpr160 antibody we used may interact with epitopes shared with several other GPCRs" , suggesting that complementary validation approaches remain important.

How do different fixation methods affect GPR160 antibody binding and specificity?

In general, GPCR antibody binding can be significantly affected by fixation protocols due to their transmembrane nature and complex tertiary structure. Based on general principles for GPCR immunodetection and the limited information from the search results, researchers should consider:

• Fixative selection:

  • Paraformaldehyde (PFA) at 4% is commonly used for GPCRs and likely suitable for GPR160

  • Methanol fixation often denatures membrane proteins and may disrupt epitope recognition

  • Glutaraldehyde may provide stronger fixation but could reduce antibody accessibility to epitopes

• Fixation duration:

  • Overfixation may mask epitopes, particularly for transmembrane proteins

  • Brief fixation may be insufficient to maintain tissue architecture

  • Optimization of fixation time specifically for GPR160 detection would be valuable

• Antigen retrieval:

  • Heat-induced epitope retrieval may be necessary after stronger fixation

  • pH-controlled buffer systems might affect accessibility to the second extracellular loop targeted by the Pa5-33650 antibody

  • Proteolytic retrieval methods should be tested for comparative efficacy

• Fresh-frozen versus fixed tissue:

  • The search results mention successful detection in both cultured cells and tissue slices

  • Fresh-frozen sections may preserve epitopes better but sacrifice structural integrity

  • Fixed-frozen sections offer a potential compromise

• Post-fixation treatments:

  • Permeabilization methods (detergents, freeze-thaw cycles) may differentially affect access to various domains of GPR160

  • Blocking procedures should be optimized to reduce non-specific binding

Given the noted concerns about potential cross-reactivity with other GPCRs , systematic evaluation of how different fixation methods affect specific versus non-specific binding would be particularly valuable for advancing GPR160 research methods.

What quality control measures are essential when using GPR160 antibodies in different experimental contexts?

When using GPR160 antibodies across different experimental contexts, several quality control measures are essential to ensure reliable and interpretable results:

• Antibody validation:

  • Western blotting to confirm specific band detection at the expected molecular weight

  • siRNA knockdown to demonstrate reduced signal with reduced target expression

  • Use of positive control tissues/cells with known GPR160 expression

  • Testing in GPR160 knockout or overexpression systems when available

• Specificity controls:

  • The search results emphasize potential cross-reactivity concerns: "the GPR160 antibody we used may interact with epitopes shared with several other GPCRs"

  • Controls should include:

    • Preabsorption with immunizing peptide

    • Testing in tissues not expected to express GPR160

    • Comparison of multiple antibodies targeting different GPR160 epitopes

• Technical controls:

  • Inclusion of isotype controls for immunoneutralization experiments

  • Secondary antibody-only controls for immunostaining

  • Titration of antibody concentration to determine optimal signal-to-noise ratio

  • Batch controls when processing multiple samples

• Context-specific validations:

  • For immunohistochemistry: Test multiple fixation protocols and antigen retrieval methods

  • For immunoprecipitation: Validate precipitation efficiency

  • For neutralization experiments: Confirm antibody stability in physiological conditions

  • For cell culture: Compare expression patterns with in vivo tissue to account for potential differences

• Multiple detection methods:

  • Combine antibody-based detection with complementary approaches

  • The search results mention validation using "a combination of approaches" including RNAscope for transcript detection

• Documentation and reporting:

  • Record detailed antibody information (manufacturer, catalog number, lot number)

  • Document all experimental conditions thoroughly

  • Report all quality control measures performed

These measures are particularly important given the concerns raised in the search results about antibody specificity and the differences observed between in vitro and in vivo expression patterns .